| Literature DB >> 31318128 |
L J Estcourt1,2.
Abstract
CLINICAL QUESTION: In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage? EVIDENCE FROM TRIAL: In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP.Entities:
Keywords: RCT; caplacizumab; plasma exchange; thrombotic thrombocytopenic pupura
Year: 2019 PMID： 31318128 DOI： 10.1111/tme.12615
Source DB: PubMed Journal: Transfus Med ISSN： 0958-7578 Impact factor: 2.019